Skip Navigation

JNCI Journal of the National Cancer Institute 2005 97(22):1631; doi:10.1093/jnci/dji447
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Travis, K.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Travis, K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 Oxford University Press

MEMO TO THE MEDIA

Press Release

Tamoxifen Reduces Risk of Breast Cancer, Follow-Up Study Confirms

Kate Travis

jncimedia@oxfordjournals.org
301-841-1287
Journal of the National Cancer Institute

The first 10% of the full text of this article appears below.

Data from additional years of follow-up of a large randomized placebo-controlled clinical trial of tamoxifen for the prevention of breast cancer confirm that the drug reduces the risk of invasive and noninvasive breast cancer, according to a report that appears in the November 16 issue of the Journal of the National Cancer Institute.

The National Surgical Adjuvant . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?